Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Hepatology

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/jhep.2003.50316PMID 12883485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease

  2002cited by this paper
• Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease.

  2002cited by this paper
• Platelet activation in obese women: role of inflammation and oxidant stress.

  2002cited by this paper
• Metformin in non-alcoholic steatohepatitis.

  2002cited by this paper
• Is bacterial ash the flash that ignites NASH

  2001cited by this paper
• Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

  2001cited by this paper
• Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes

  2001cited by this paper
• A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

  2001cited by this paper
• Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis.

  2001cited by this paper
• Treatment of Nonalcoholic Fatty Liver: Present and Emerging Therapies

  2001cited by this paper
• The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis

  2001cited by this paper
• Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet.

  2000cited by this paper
• Serum hyaluronan ‐ a non‐invasive test for diagnosing liver cirrhosis

  2000cited by this paper
• Metformin reverses fatty liver disease in obese, leptin-deficient mice

  2000cited by this paper
• Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.

  2000cited by this paper
• Cytokines in alcoholic and nonalcoholic steatohepatitis.

  2000cited by this paper
• Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study.

  2000cited by this paper
• Increased monocyte nuclear factor-kappaB activation and tumor necrosis factor production in alcoholic hepatitis.

  2000cited by this paper
• Treatment with glutathione precursor decreases cytokine activity.

  1999cited by this paper
• Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

  1999cited by this paper
• Cytokines in Alcoholic Liver Disease

  1999cited by this paper
• Fatty liver--an additional and treatable feature of the insulin resistance syndrome.

  1999cited by this paper
• Increased urinary F2-isoprostane excretion in alcoholic liver disease.

  1999cited by this paper
• Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice

  1999cited by this paper
• Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro.

  1999cited by this paper
• Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice.

  1999cited by this paper
• Steatohepatitis: a tale of two "hits"?

  1998cited by this paper
• S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide-induced hepatic injury.

  1998cited by this paper
• MECHANISMS OF HEPATIC INJURY IN ALCOHOLIC LIVER DISEASE

  1998cited by this paper
• Hyperhyaluronanemia in alcoholic hepatitis is associated with increased levels of circulating soluble intercellular adhesion molecule-1.

  1998cited by this paper
• Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat.

  1997cited by this paper
• Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat

  1997cited by this paper
• Choline deficiency augments and antibody to tumor necrosis factor-alpha attenuates endotoxin-induced hepatic injury.

  1997cited by this paper
• Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

  1997cited by this paper
• Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis.

  1997cited by this paper
• Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.

  1996cited by this paper
• Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study

  1996cited by this paper
• Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression.

  1995cited by this paper
• Cytokine gene expression by Kupffer cells in experimental alcoholic liver disease

  1995cited by this paper
• Antibiotics prevent liver injury in rats following long-term exposure to ethanol.

  1995cited by this paper
• Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol-fed rats.

  1994cited by this paper
• Use of reverse transcription–polymerase chain reaction to evaluate in vivo cytokine gene expression in rats fed ethanol for long periods

  1994cited by this paper
• Inactivation of Kupffer cells prevents early alcohol‐induced liver injury

  1994cited by this paper
• Use of reverse transcription-polymerase chain reaction to evaluate in vivo cytokine gene expression in rats fed ethanol for long periods.

  1994cited by this paper
• Increased plasma interleukin‐8 concentrations in alcoholic hepatitis

  1993cited by this paper
• Increased plasma interleukin-6 concentrations in alcoholic hepatitis.

  1992cited by this paper
• Tumor necrosis factor in alcohol enhanced endotoxin liver injury.

  1992cited by this paper
• Cytokines and liver disease.

  1991cited by this paper
• Circulating tumor necrosis factor, interleukin‐1 and interleukin‐6 concentrations in chronic alcoholic patients

  1991cited by this paper
• Effect of weight reduction on hepatic abnormalities in overweight patients.

  1990cited by this paper
• Increased tumor necrosis factor production by monocytes in alcoholic hepatitis

  1989cited by this paper
• Dietary guidelines for healthy American adults. A statement for physicians and health professionals by the Nutrition Committee, American Heart Association.

  1986cited by this paper
• Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

  1980cited by this paper

• Diosmetin alleviates TNFα-induced liver inflammation by improving liver sinusoidal endothelial cell dysfunction.

  2025cites this paper
• S2k-Leitlinie Klinische Ernährung in der Hepatologie

  2024cites this paper
• Increased NAFLD risk in newly diagnosed patients with RA during the first 4 years of follow-up: a nationwide, population-based cohort study

  2024cites this paper
• The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)

  2024cites this paper
• Non-alcoholic fatty liver disease is associated with coronary flow reserve impairment: A pilot meta-analysis

  2024cites this paper
• Oxidative Stress as a Target for Non-Pharmacological Intervention in MAFLD: Could There Be a Role for EVOO?

  2024cites this paper
• Protective Role of Lycopene in Subjects with Liver Disease: NUTRIHEP Study

  2024cites this paper
• Vitamin E for people with non‐alcoholic fatty liver disease

  2024cites this paper
• Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review

  2023cites this paper
• Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease: An Incomplete Jigsaw Puzzle.

  2023cites this paper
• In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions

  2023cites this paper
• The Effect of High-Intensity Interval Exercise on Short-Term Glycaemic Control, Serum Level of Key Mediator in Hypoxia and Pro-Inflammatory Cytokines in Patients with Type 1 Diabetes—An Exploratory Case Study

  2023cites this paper
• Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway

  2023cites this paper
• Effect of Dietary Intervention, with or without Cointerventions, on Inflammatory Markers in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

  2023influential citation
• GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling.

  2023cites this paper
• Mechanical study of alisol B 23-acetate on methionine and choline deficient diet-induced nonalcoholic steatohepatitis based on untargeted metabolomics.

  2023cites this paper
• Fibrosis-4 Index Is Closely Associated with Arterial Damage and Future Risk of Coronary Heart Disease in Type 2 Diabetes

  2022cites this paper
• Advancements in MAFLD Modeling with Human Cell and Organoid Models

  2022cites this paper
• Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

  2022cites this paper
• Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression

  2022cites this paper
• The biological clock enhancer nobiletin ameliorates steatosis in obesity by restoring aberrant hepatic circadian rhythm.

  2022cites this paper
• The Roles of TNF Signaling Pathways in Metabolism of Bone Tumors

  2022cites this paper
• Mitigation of MAFLD in High Fat-High Sucrose-Fructose Fed Mice by a Combination of Genistein Consumption and Exercise Training

  2022cites this paper
• NAFLD as the metabolic hallmark of obesity

  2022cites this paper
• Cyclosorus terminans Extract Ameliorates Insulin Resistance and Non-Alcoholic Fatty Liver Disease (NAFLD) in High-Fat Diet (HFD)-Induced Obese Rats

  2022cites this paper
• Metabolic Messengers: tumour necrosis factor

  2021cites this paper
• Satellite cell content and muscle regeneration in a mouse model of NAFLD.

  2021cites this paper
• Comparison of Body Mass Index, Smoking, Vitamin E and Type of Oil Consumed between Patients Suffering from Non-alcoholic Fatty Liver Disease versus Non-affected Patients: A Case-Control Study

  2021cites this paper
• Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity

  2021cites this paper
• Comparison of Body Mass Index, Smoking, Vitamin E and Type of Oil Consumed Between Patients Suffering From Non-alcoholic Fatty Liver Disease versus Non-affected Patients: A Case-Control Study

  2021cites this paper
• Identification of hub genes and pathways in nonalcoholic steatohepatitis by integrated bioinformatics analysis

  2021cites this paper
• Circulating tumor necrosis factor‐α levels in non‐alcoholic fatty liver disease: A systematic review and a meta‐analysis

  2021cites this paper
• Role of the inflammasome, gasdermin D, and pyroptosis in non‐alcoholic fatty liver disease

  2021cites this paper
• Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review.

  2021cites this paper
• Method for diagnosing non-alcoholic liver steatosis

  2021cites this paper
• Prevalence of asymptomatic bronchiectasis and associations among the health screening population in South Korea

  2021cites this paper
• Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease

  2021cites this paper
• Alleviation of non-alcoholic fatty liver disease by Huazhi Fugan Granules is associated with suppression of TLR4/NF-κB signaling pathway.

  2021cites this paper
• The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.

  2021cites this paper
• Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.

  2021cites this paper
• Hepatic Response of Magnesium-Restricted Wild Type Mice

  2021influential citation
• Plasma Krebs Cycle Intermediates in Nonalcoholic Fatty Liver Disease

  2020cites this paper
• [Review Articles].

  2020cites this paper
• Non-alcoholic Fatty Liver Disease: A Global Public Health Issue

  2020cites this paper
• Accelerating Effects of Vitamin E Supplementation on Liver Enzyme Normalization in Children with Acute Hepatitis A Infection; a Single-Blinded Clinical Trial

  2020cites this paper
• INSIGHTS INTO THE IMPACT OF FXR ACTIVATION ON HEPATIC AUTOPHAGY IN A NON-ALCOHOLIC STEATOHEPATITIS MODEL

  2020cites this paper
• Accelerating Effects of Vitamin E Supplementation on Liver Enzyme Normalization in Children with Acute Hepatitis A Infection; a Single-Blinded Clinical Trial

  2020cites this paper
• Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound—Toward Improved Detection of Liver Impairment

  2020cites this paper
• Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease

  2020cites this paper
• Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges

  2020cites this paper
• Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease

  2020cites this paper
• TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice

  2020cites this paper
• Pathophysiological Changes During Ischemia-reperfusion Injury in Rodent Hepatic Steatosis

  2020cites this paper
• Predicting Nonalcoholic Fatty Liver Disease through a Panel of Plasma Biomarkers and MicroRNAs in Female West Virginia Population

  2020cites this paper
• Non-viral liver diseases: pathogenetic approaches to therapy

  2019cites this paper
• Circulating Levels of Pro-inflammatory Cytokines in Patients with Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.

  2019cites this paper
• Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients

  2019cites this paper
• Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?

  2019cites this paper
• Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack

  2019cites this paper
• Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review.

  2019cites this paper
• Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4

  2019influential citation
• ESPEN guideline on clinical nutrition in liver disease.

  2019cites this paper
• Obesity in the Pathophysiology of Diabetes

  2019cites this paper
• Hepatoprotective Effect of Jianpi Huoxue Formula on Nonalcoholic Fatty Liver Disease Induced by Methionine-Choline-Deficient Diet in Rat

  2019cites this paper
• Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis

  2019cites this paper
• Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice

  2019cites this paper
• Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities

  2019cites this paper
• Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression.

  2019cites this paper
• Vitamin E in Nonalcoholic Fatty Liver Disease

  2019cites this paper
• Inflammation and IL 6: A possible role in NAFLD

  2019influential citation
• Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study

  2019cites this paper
• Non-Alcoholic Fatty Liver Disease.

  2019cites this paper
• Future therapy for non‐alcoholic fatty liver disease

  2018cites this paper
• Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH

  2018cites this paper
• Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men

  2018cites this paper
• Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells

  2018cites this paper
• Human‐based systems: Mechanistic NASH modelling just around the corner?

  2018cites this paper
• Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study

  2018cites this paper
• Periodontitis and prevalence of elevated aminotransferases in the Hispanic Community Health Study/Study of Latinos

  2018cites this paper
• Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth?

  2018cites this paper
• Nutrition and Lifestyle Modifications in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease

  2018cites this paper
• Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis

  2018cites this paper
• Prevalence and predictive value of high‐positive rheumatoid factor and anti‐citrullinated protein antibody levels in nonarthritic patients with chronic hepatitis C infection

  2018cites this paper
• mTOR Activation in Liver Tumors Is Associated with Metabolic Syndrome and Non-Alcoholic Steatohepatitis in Both Mouse Models and Humans

  2018cites this paper
• Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007–2010

  2018cites this paper
• Nonalcoholic Fatty Liver Disease

  2017cites this paper
• The relationship of serum alanine aminotransferase normal-range levels to arterial stiffness and metabolic syndrome in non-drinkers and drinkers: a Chinese community-based analysis

  2017cites this paper
• The Relationship Between Tamoxifen‐associated Nonalcoholic Fatty Liver Disease and the Prognosis of Patients With Early‐stage Breast Cancer

  2017cites this paper
• Salicornia Extract Ameliorates Salt-Induced Aggravation of Nonalcoholic Fatty Liver Disease in Obese Mice Fed a High-Fat Diet.

  2017cites this paper
• Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.

  2017cites this paper
• The pharmacological management of NAFLD in children and adolescents

  2017cites this paper
• Effect of rosiglitazone on the expression of tumor necrosis factor-α in the liver tissue of mice with non-alcoholic steatohepatitis

  2017cites this paper
• Hepatic interleukin-6 production is maintained during endotoxin tolerance and facilitates lipid accumulation.

  2017cites this paper
• Regulation of HepG2 Fat Metabolism by IL1β and IL1 Receptor Antagonist

  2017cites this paper
• Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.

  2017cites this paper
• Pharmacotherapy for Non-alcoholic Fatty Liver Disease

  2017cites this paper
• New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)

  2017cites this paper
• ROS Endothelial Dysfunction in Non-Alcoholic Fatty Liver Disease

  2017cites this paper
• Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease

  2017cites this paper